논문 18 페이지 | PnH

최근소식

회사소개 사업소개 치료기술 암종별치료 최근소식 고객센터

논문 치료사례 동영상게시판 사진게시판

논문

번호 제목 날짜

215

2024년 면역세포치료 동향 3월

2024년 면역세포치료 동향 3월
2024-05-31
214

2024년 Nature Biotechnology:In vivo human T cell engineering with enveloped delivery vehicles

2024년 Nature Biotechnology:In vivo human T cell engineering with enveloped delivery vehicles
2024-05-31
213

2024년 Science Translational Medicine:Causality-enriched epigenetic age uncouples damage and adaptation

2024년 Science Translational Medicine:Causality-enriched epigenetic age uncouples damage and adaptation
2024-05-31
212

2024년 Nature Communications:CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes

2024년 Nature Communications:CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes
2024-05-31
211

2024년 Nature Biotechnology:An oncolytic virus–T cell chimera for cancer immunotherapy

2024년 Nature Biotechnology:An oncolytic virus–T cell chimera for cancer immunotherapy
2024-05-31
210

Proceedings of the National Academy of Sciences:Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class

Proceedings of the National Academy of Sciences:Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class
2024-05-31
209

2024년 Cell Reports Medicine :Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism

2024년 Cell Reports Medicine :Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism
2024-05-31
208

2024년 Nature :Senolytic CAR-T cells reverse senescence-associated pathologies

2024년 Nature :Senolytic CAR-T cells reverse senescence-associated pathologies
2024-05-31
207

2024년 FDA승인된 CAR-T세포치료 와 중국에서 승인된 CAR-T세포치료

2024년 FDA승인된 CAR-T세포치료 와 중국에서 승인된 CAR-T세포치료
2024-05-31
206

2024년 Nature Medicine:Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

2024년 Nature Medicine:Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
2024-05-31